R-hydroxynitrillyases havign improved substrate tolerance and the use thereof
    4.
    发明申请
    R-hydroxynitrillyases havign improved substrate tolerance and the use thereof 失效
    R-hydroxynitrillyases有利于改善底物耐受性及其用途

    公开(公告)号:US20060105434A1

    公开(公告)日:2006-05-18

    申请号:US10548271

    申请日:2004-02-24

    IPC分类号: C12P13/04 C12P13/00 C12N9/88

    CPC分类号: C12P13/004 C12N9/88

    摘要: The invention related to R-hydroxynitrillyases from the family of Rosaceae that are characterized by an improved substrate tolerance and increased stability. In the active center of the R-hydroxynitrillyases either a) an alanine group is substituted by glycine, valine, leucine, isoleucine, or phenylalanine or b) a phenylalanine group is substituted by alanine, glycine valine, leucine or isoleucine, or c) a leucine group is substituted by alanine, glycine, valine, isoleucine or phenylalanine, or d) an isoleucine group is substituted by alanine, glycine, valine, leucine or phenylalanine. The invention also relates to the use of these lyases in the production of enantiomer-pure R- or S-cyanohydrines.

    摘要翻译: 本发明涉及来自蔷薇科家族的R-羟基亚硝酸酯酶,其特征在于改善的底物耐受性和增加的稳定性。 或者a)丙氨酸被甘氨酸,缬氨酸,亮氨酸,异亮氨酸或苯丙氨酸取代,或b)苯丙氨酸被丙氨酸,甘氨酸缬氨酸,亮氨酸或异亮氨酸取代,或c) 亮氨酸被丙氨酸,甘氨酸,缬氨酸,异亮氨酸或苯丙氨酸取代,或d)异亮氨酸被丙氨酸,甘氨酸,缬氨酸,亮氨酸或苯丙氨酸取代。 本发明还涉及这些裂解酶在制备对映异构体纯的R-或S-氰基中的用途。

    R-hydroxynitrillyases having improved substrate tolerance and the use thereof
    5.
    发明授权
    R-hydroxynitrillyases having improved substrate tolerance and the use thereof 失效
    具有改善的基质耐受性的R-羟基亚硝酸酯酶及其用途

    公开(公告)号:US07572608B2

    公开(公告)日:2009-08-11

    申请号:US10548271

    申请日:2004-02-24

    IPC分类号: C12P13/04 C12N9/88

    CPC分类号: C12P13/004 C12N9/88

    摘要: The invention relates to R-hydroxynitrillyases from the family of Rosaceae that are characterized by an improved substrate tolerance and increased stability. In the active center of the R-hydroxynitrillyases either a) an alanine group is substituted by glycine, valine, leucine, isoleucine, or phenylalanine or b) a phenylalanine group is substituted by alanine, glycine valine, leucine or isoleucine, or c) a leucine group is substituted by alanine, glycine, valine, isoleucine or phenylalanine, or d) an isoleucine group is substituted by alanine, glycine, valine, leucine or phenylalanine. The invention also relates to the use of these lyases in the production of enantiomer-pure R- or S-cyanohydrines.

    摘要翻译: 本发明涉及来自蔷薇科的R-羟基亚硝酸酯酶,其特征在于改善的基质耐受性和增加的稳定性。 或者a)丙氨酸被甘氨酸,缬氨酸,亮氨酸,异亮氨酸或苯丙氨酸取代,或b)苯丙氨酸被丙氨酸,甘氨酸缬氨酸,亮氨酸或异亮氨酸取代,或c) 亮氨酸被丙氨酸,甘氨酸,缬氨酸,异亮氨酸或苯丙氨酸取代,或d)异亮氨酸被丙氨酸,甘氨酸,缬氨酸,亮氨酸或苯丙氨酸取代。 本发明还涉及这些裂解酶在制备对映异构体纯的R-或S-氰基中的用途。

    Mutant Aox1 Promoters
    7.
    发明申请
    Mutant Aox1 Promoters 有权
    突变型Aox1启动子

    公开(公告)号:US20080153126A1

    公开(公告)日:2008-06-26

    申请号:US11817005

    申请日:2006-02-23

    CPC分类号: C12N15/815 C12Y101/03013

    摘要: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (−784 to −719), nucleotides 170 to 191 (−784 to −763), nucleotides 192 to 213 (−762 to −741), nucleotides 192 to 210 (−762 to −744), nucleotides 207 to 209 (−747 to −745), nucleotides 214 to 235 (−740 to −719), nucleotides 304 to 350 (−650 to −604), nucleotides 364 to 393 (−590 to −561), nucleotides 434 to 508 (−520 to −446), nucleotides 509 to 551 (−445 to −403), nucleotides 552 to 560 (−402 to −394), nucleotides 585 to 617 (−369 to −337), nucleotides 621 to 660 (−333 to −294), nucleotides 625 to 683 (−329 to −271), nucleotides 736 to 741 (−218 to −213), nucleotides 737 to 738 (−217 to −216), nucleotides 726 to 755 (−228 to −199), nucleotides 784 to 800 (−170 to −154) or nucleotides 823 to 861 (−131 to −93) of Seq ID No. 1, and combinations thereof.

    摘要翻译: 包含选自以下的至少一个突变的野生型巴斯德毕赤酵母AOX1启动子(SEQ ID No.1)的突变型巴斯德毕赤酵母醇氧化酶1(AOX1)启动子:a)转录因子结合位点(TFBS),b )核苷酸170至235(-784至-719),核苷酸170至191(-784至-763),核苷酸192至213(-762至-741),核苷酸192至210(-762至-744),核苷酸 207至209(-747至-745),核苷酸214至235(-740至-719),核苷酸304至350(-650至-604),核苷酸364至393(-590至-561),核苷酸434至 508(-520至-446),核苷酸509至551(-445至-403),核苷酸552至560(-402至-394),核苷酸585至617(-369至-337),核苷酸621至660( -333至-294),核苷酸625至683(-329至-271),核苷酸736至741(-218至-213),核苷酸737至738(-217至-216),核苷酸726至755(-228 至-199),Seq ID No.1的核苷酸784至800(-170至-154)或核苷酸823至861(-131至-93) 及其组合。

    CYTOCHROME P450 OXYGENASES
    9.
    发明申请
    CYTOCHROME P450 OXYGENASES 有权
    CYTOCHROME P450氧化剂

    公开(公告)号:US20120184015A1

    公开(公告)日:2012-07-19

    申请号:US13323398

    申请日:2011-12-12

    IPC分类号: C12N9/02

    摘要: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

    摘要翻译: 提供了编码细胞色素P450变体的核酸。 细胞色素P450变体具有比相应的野生型或亲本细胞色素P450酶更高的烷烃氧化能力,烯烃氧化能力和/或较高的有机溶剂耐受性。 优选的野生型细胞色素P450是细胞色素P450 BM-3。 优选的细胞色素P450变体包括具有改善含有少于8个碳原子的烷烃和环氧化烯烃羟基化能力以及对应于细胞色素P450 BM-3的V78A,H236Q和E252G的氨基酸取代的那些变体。 优选的细胞色素P450变体还包括在包含共溶剂如DMSO和THF的溶液中具有改善的羟基化活性的那些,并且具有对应于细胞色素P450 BM-3的T235A,R471A,E494K和S1024E的氨基酸取代。

    Mutant AOX1 Promoters
    10.
    发明申请
    Mutant AOX1 Promoters 有权
    突变型AOX1启动子

    公开(公告)号:US20100196913A1

    公开(公告)日:2010-08-05

    申请号:US12759763

    申请日:2010-04-14

    CPC分类号: C12N15/815 C12Y101/03013

    摘要: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (−784 to −719), nucleotides 170 to 191 (−784 to −763), nucleotides 192 to 213 (−762 to −741), nucleotides 192 to 210 (−762 to −744), nucleotides 207 to 209 (−747 to −745), nucleotides 214 to 235 (−740 to −719), nucleotides 304 to 350 (−650 to −604), nucleotides 364 to 393 (−590 to −561), nucleotides 434 to 508 (−520 to −446), nucleotides 509 to 551 (−445 to −403), nucleotides 552 to 560 (−402 to −394), nucleotides 585 to 617 (−369 to −337), nucleotides 621 to 660 (−333 to −294), nucleotides 625 to 683 (−329 to −271), nucleotides 736 to 741 (−218 to −213), nucleotides 737 to 738 (−217 to −216), nucleotides 726 to 755 (−228 to −199), nucleotides 784 to 800 (−170 to −154) or nucleotides 823 to 861 (−131 to −93) of Seq ID No. 1, and combinations thereof.

    摘要翻译: 一种突变巴斯德毕赤酵母醇氧化酶1(AOX1)野生型毕赤酵母AOX1启动子的启动子(序列号1),其包括选自由以下组成的组中选择的至少一个突变:a)转录因子结合位点(TFBS),B )核苷酸170到235(-784到-719),核苷酸170至191(-784到-763),核苷酸192至213(-762到-741),核苷酸192至210(-762到-744),核苷酸 207至209(-747到-745),核苷酸214至235(-740到-719),核苷酸304至350(-650到-604),核苷酸364至393(-590到-561),核苷酸434到 508(-520到-446),核苷酸509至551(-445到-403),核苷酸552至560(-402到-394),核苷酸585至617(-369到-337),核苷酸621至660( -333到-294),核苷酸625至683(-329到-271),核苷酸736至741(-218到-213),核苷酸737至738(-217到-216),核苷酸726至755(-228 至-199),核苷酸784至800( 170至-154)或核苷酸SEQ ID No.1中,和它们的组合的823至861(-131到-93)。